Pharmacological Reports
October 1, 2023
Priscila Vázquez-león, Abraham Miranda-Páez, Hugo Sánchez-Castillo et al.
Periaqueductal gray matter (PAG) is a brain region rich in kappa-opioid receptors (KOR). KOR in PAG mediates behavioral responses related to pain integration, and panic response, among others. Its participation in the addiction phenomena has been poorly studied. Hence, this preliminary study explored the pharmacological effects of KOR stimulation/blockade in dorsal-PAG (D-PAG) during alcohol...
IBRO Neuroscience Reports
October 1, 2023
Mariana Pazos, Ignacio Carrera, Giselle Prunell
1 citation
Ayahuasca is a psychedelic beverage originally from the Amazon rainforest used in different shamanic settings for a variety of medicinal, spiritual, and cultural purposes. It is prepared by decoction of the vine Banisteriopsis caapi, source of β-carboline alkaloids, and, Psychotria viridis containing the classic psychedelic N,N-dimethyltryptamine (DMT). As part of the “renaissance of...
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
October 1, 2023
Kelan Thomas
In coming years, pharmacists will begin fielding more questions regarding psychedelic medicine, most notably with the imminent FDA approval of 3,4-methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder (PTSD) expected in 2024 and psilocybin for major depressive disorder (MDD) likely in 2025. Psychedelics are unique medications in many ways, but especially due to the mental...
Psychopharmacology
October 1, 2023
Ana Carolina Dutra-Tavares, Thainá P Souza, Juliana O Silva et al.
Sex-biased differences in schizophrenia are evident in several features of the disease, including symptomatology and response to pharmacological treatments. As a neurodevelopmental disorder, these differences might originate early in life and emerge later during adolescence. Considering that the disruption of the glutamatergic system during development is known to contribute to schizophrenia,...
IBRO Neuroscience Reports
October 1, 2023
Aneta Petrušková, Eva‐maria Weiss, Debarpan Guhathakurta et al.
Serotonergic psychedelics (SP) such as psilocybin, LSD or DMT pose significant potential for development of new strategies in treating neuropsychiatric disorders including major depression disorder, post-traumatic stress disorder and addiction. To bring these substances to clinical application, however, better understanding of the mechanisms behind their effects on many levels, including...
Journal of Parapsychology
October 1, 2023
Gerhard Mayer
This paper presents some results of a qualitative interview study with contemporary magicians that was carried out in two phases in German-speaking countries.The greater part of the data was collected in 2004-2005 and covered a broad range of topics.The topics presented here include (1) paranormal experiences of magicians, (2) evaluation of magical practice, and (3) magic in the laboratory.To...
History of Pharmacy and Pharmaceuticals
October 1, 2023
Ido Hartogsohn
9 citations
Abstract The term “corporadelic” signifies “manifesting corporate structures, ethos, or logic within the context of the psychedelic landscape.” It points to a relatively novel phenomena in the history of psychedelics: the appropriation of these psychoactive agents by for-profit corporations and the integration of psychedelic use into corporate setting. Set and setting is a fundamental concept...
European Archives of Psychiatry and Clinical Neuroscience
October 1, 2023
Juliana Mendes Rocha, José A S Reis, José Carlos Bouso et al.
21 citations
Ibogaine is a psychoactive alkaloid derived from the west-African shrub Tabernanthe iboga. Western cultures are increasing the interest for the substance due to its claimed anti addictive properties, although the evidence supporting this effect is still preliminary. The use of ibogaine often occurs with no medical supervision in uncontrolled settings, and its use has been associated with...
CPT: Pharmacometrics & Systems Pharmacology
October 1, 2023
Emma Eckernäs, Jeroen Koomen, Christopher Timmermann et al.
1 citation
N,N-dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its short half-life, continuous infusion of DMT has been proposed to extend the psychedelic experience and potential therapeutic effects. The primary aim of this work was to design an infusion protocol for DMT based on a desired level of psychedelic...
Anesthesiology
October 1, 2023
Akash Goel, Yeshith Rai, Shayan Sivadas et al.
29 citations
Chronic pain is a public health concern that affects approximately 1.5 billion people globally. Conventional therapeutic agents including opioid and non-opioid analgesics have been associated with adverse side effects, issues with addiction, and ineffective analgesia. Novel agents repurposed to treat pain via different mechanisms are needed to fill the therapeutic gap in chronic pain...